Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.

ABSTRACT:

What is known and objectives

Although the apixaban Food and Drug Administration (FDA) package insert recommends dose reduction in patients administered dual strong inhibitors of p-glycoprotein (P-gp) and cytochrome P-450 (CYP) 3A4, there are limited published data regarding potential drug-drug interactions between apixaban (Eliquis) and common p-glycoprotein (P-gp) and CYP3A4 inhibitors co-administered with statins. The aim of this study was to investigate the degree of elevation relative to apixaban serum peak and trough concentration after the co-administration of amiodarone, diltiazem and statins (atorvastatin, rosuvastatin and simvastatin).

Methods

Patients prescribed apixaban 5mg twice daily for at least one week were identified from the anticoagulation clinic database

SUBMITTER: Milner E 

PROVIDER: S-EPMC9305439 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature